Your browser doesn't support javascript.
loading
HPV cervical infections and serological status in vaccinated and unvaccinated women.
Murall, Carmen Lía; Reyné, Bastien; Selinger, Christian; Bernat, Claire; Boué, Vanina; Grasset, Sophie; Groc, Soraya; Rahmoun, Massilva; Bender, Noemi; Bonneau, Marine; Foulongne, Vincent; Graf, Christelle; Picot, Eric; Picot, Marie-Christine; Tribout, Vincent; Waterboer, Tim; Bravo, Ignacio G; Reynes, Jacques; Segondy, Michel; Boulle, Nathalie; Alizon, Samuel.
Afiliación
  • Murall CL; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Reyné B; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Selinger C; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Bernat C; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Boué V; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Grasset S; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Groc S; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Rahmoun M; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Bender N; German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Im Neuenheimer Feld 280, Heidelberg, Germany.
  • Bonneau M; Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Unversity of Montpellier, France.
  • Foulongne V; Department of Biology & Pathology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Graf C; Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Unversity of Montpellier, France.
  • Picot E; Center for Free Information, Screening and Diagnosis (CeGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Picot MC; Department of Medical Information (DIM), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Tribout V; Center for Free Information, Screening and Diagnosis (CeGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Waterboer T; German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Im Neuenheimer Feld 280, Heidelberg, Germany.
  • Bravo IG; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.
  • Reynes J; Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Segondy M; Department of Biology & Pathology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Boulle N; Department of Biology & Pathology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Alizon S; Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France. Electronic address: samuel.alizon@cnrs.fr.
Vaccine ; 38(51): 8167-8174, 2020 12 03.
Article en En | MEDLINE | ID: mdl-33168348
ABSTRACT
Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Neoplasias del Cuello Uterino / Infecciones por Papillomavirus / Alphapapillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Vaccine Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Neoplasias del Cuello Uterino / Infecciones por Papillomavirus / Alphapapillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans País/Región como asunto: Europa Idioma: En Revista: Vaccine Año: 2020 Tipo del documento: Article País de afiliación: Francia
...